| Literature DB >> 26075616 |
Gernot Längst1, Laura Manelyte2.
Abstract
Chromatin remodelers are key players in the regulation of chromatin accessibility and nucleosome positioning on the eukaryotic DNA, thereby essential for all DNA dependent biological processes. Thus, it is not surprising that upon of deregulation of those molecular machines healthy cells can turn into cancerous cells. Even though the remodeling enzymes are very abundant and a multitude of different enzymes and chromatin remodeling complexes exist in the cell, the particular remodeling complex with its specific nucleosome positioning features must be at the right place at the right time in order to ensure the proper regulation of the DNA dependent processes. To achieve this, chromatin remodeling complexes harbor protein domains that specifically read chromatin targeting signals, such as histone modifications, DNA sequence/structure, non-coding RNAs, histone variants or DNA bound interacting proteins. Recent studies reveal the interaction between non-coding RNAs and chromatin remodeling complexes showing importance of RNA in remodeling enzyme targeting, scaffolding and regulation. In this review, we summarize current understanding of chromatin remodeling enzyme targeting to chromatin and their role in cancer development.Entities:
Keywords: arrest model; cancer; chromatin remodeler; non-coding RNA; search mechanism
Year: 2015 PMID: 26075616 PMCID: PMC4488666 DOI: 10.3390/genes6020299
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Figure 1Organization of remodeler families defined by their catalytic and flanking domains. All remodeling enzymes consist of a shared ATPase domain and unique flanking domains.
Targeting signals recognized by chromatin remodelers.
| Molecular Interaction | Description Selected Examples | Refs. |
|---|---|---|
| DNA secondary structure, G-quadruplexes, DNA linker length, DNA modification | [ | |
| Examples: Brg1, Chd1, ISWI, ACF, NURF, Mi-2, Snf2H, Tip5/NoRC, ATRX, NURD, RSC | ||
| Noncoding RNA secondary structure | [ | |
| Examples: ISWI, Tip5/NoRC, Brg1 | ||
| H3 acetylation recognized by bromo domains, methylation—Chromo domains, PHD. H4 tails are required for SANT domain binding. | [ | |
| Examples: Tip5/NoRC, RSC, ISWI, Chd4 | ||
| Histone variants mH2A, H2A.Z, H2A.X | [ | |
| Examples: ATRX, Ino80, WICH, Lsh | ||
| Transcription factors and other protein-protein interactions | [ | |
| Examples: NoRC, NuRD, Snf2H |
Figure 2DNA-sequence and the subunit composition of the chromatin remodeling complexes determine the affinity and outcome of the reaction. The 280 bp ribosomal RNA gene promoter sequence and the 208 bp 601 sequence were reconstituted into the nucleosomes using the salt dialysis method. The rRNA gene promoter sequence exhibits several translational positions of the nucleosome, whereas the 601 exhibits a single nucleosome position, as described (lane 1). The differentially labeled nucleosomal DNA templates were mixed and either incubated with increasing concentrations of Snf2H or NoRC in the presence of ATP (lanes 2–6 and 7–14) [55]. Nucleosome positions were analyzed by native polyacrylamide gel electrophoresis.
Figure 3pRNA inhibits the activity of NoRC. Nucleosomes assembled on the −190 to +90 rDNA DNA fragment were incubated with NoRC, ATP and increasing concentrations of pRNA−143/−39 and pRNA−113/−39. The remodeling reactions were analyzed by EMSA. The arrowhead indicates the nucleosome at the −120/+27 position [55].
Figure 4Model describing the potential activities of deregulated chromatin remodelers in an oncogenic cell. Chromatin remodelers that involved in the repression of active genes, or maintaining genes repressed (a), might loose their activity on the particular gene. The same could occur with activities acting on repressed genes (b). Mutations in the reader domains could result in targeting of the complexes to non-genuine targets altering its activity status (c). To prevent the recruitment of inactive remodelers or to inhibit the mis-targeting of the enzymes, the currently available bromo domain inhibitors (marked with a star) may be useful.